Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arragements of Certain Officers.
On January 18, 2021, AnaptysBio, Inc. (the "Company") appointed Magda Marquet,
Ph.D. as a Class III director on its board of directors (the "Board"), effective
immediately. In addition, upon her appointment to the Board, Dr. Marquet was
appointed to serve on the Audit Committee of the Board (the "Audit Committee"),
and the Board determined that Dennis Fenton, Ph.D. would no longer serve on the
Audit Committee.
In connection with her appointment as a non-employee director of the Board, and
in accordance with the Company's existing compensation policy for non-employee
directors, Dr. Marquet received a stock option to purchase 784 shares of common
stock at an exercise price equal to the closing sale price of the common stock
on January 15, 2021, as reported by the Nasdaq Global Market, which shall vest
in full on February 12, 2021, representing a pro rata portion of the annual
retainer for service as a director for the remaining portion of the year. In
addition, the Board granted to Dr. Marquet, a stock option to purchase 11,000
shares of common stock at an exercise price equal to the closing sale price of
the common stock on January 15, 2021, as reported by the Nasdaq Global Market,
which will vest monthly over three years, subject to Dr. Marquet's continued
service to the Company.
The Company has entered into its standard form of indemnification agreement with
Dr. Marquet. The form of the indemnification agreement was previously filed by
the Company as Exhibit 10.1 to the Company's Registration Statement on Form S-1
filed with the Securities and Exchange Commission on September 9, 2015 and
incorporated by reference herein.
There are no arrangements or understandings between Dr. Marquet and any other
persons, pursuant to which Dr. Marquet was selected as a member of the Board.
There are also no family relationships among any of the Company's other
directors or executive officers and Dr. Marquet, and Dr. Marquet does not have
any direct or indirect material interest in any transaction required to be
disclosed pursuant to Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ANAPTYSBIO, INC. 
